Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy.
Nishikawa K, Koizumi W, Tsuburaya A, Suzuki M, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nishimura K, Yoshikawa T, Tsujinaka T, Sakamoto J. Nishikawa K, et al. Among authors: sakamoto j. Int J Clin Oncol. 2024 Nov 25. doi: 10.1007/s10147-024-02661-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39585516
Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer.
Nishikawa K, Koizumi W, Tsuburaya A, Yamanaka T, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nakayama N, Tsujinaka T, Sakamoto J. Nishikawa K, et al. Among authors: sakamoto j. Gastric Cancer. 2020 Jan;23(1):160-167. doi: 10.1007/s10120-019-00990-4. Epub 2019 Jul 15. Gastric Cancer. 2020. PMID: 31309387
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
Nishikawa K, Kawakami H, Shimokawa T, Fujitani K, Tamura S, Endo S, Kobayashi M, Kawada J, Kurokawa Y, Tsuburaya A, Yoshikawa T, Sakamoto J, Satoh T; for HERBIS-2, HERBIS-4A, XParTS I. I. study investigators. Nishikawa K, et al. Among authors: sakamoto j. Int J Clin Oncol. 2023 Nov;28(11):1501-1510. doi: 10.1007/s10147-023-02402-1. Epub 2023 Aug 27. Int J Clin Oncol. 2023. PMID: 37634209
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: sakamoto j. Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18. Eur J Cancer. 2015. PMID: 25797356 Free article. Clinical Trial.
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, Macdonald JS. Tsuburaya A, et al. Among authors: sakamoto j. Jpn J Clin Oncol. 2005 Nov;35(11):672-5. doi: 10.1093/jjco/hyi179. Epub 2005 Nov 7. Jpn J Clin Oncol. 2005. PMID: 16275676 Clinical Trial.
A randomized phase II trial of preoperative exercise to reduce operative risk in gastric cancer patients with metabolic syndrome: adjuvant exercise for general elective surgery (AEGES) study group.
Cho H, Tsuburaya A, Sakamoto J, Morita S, Oba K, Yoshikawa T, Miyajima N; Adjuvant Exercise for General Elective Surgery (AEGES) Study Group. Cho H, et al. Among authors: sakamoto j. Jpn J Clin Oncol. 2008 Jan;38(1):71-3. doi: 10.1093/jjco/hym134. Epub 2008 Jan 17. Jpn J Clin Oncol. 2008. PMID: 18202030 Clinical Trial.
A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, Miyashita Y, Sakamoto J. Yoshikawa T, et al. Among authors: sakamoto j. Jpn J Clin Oncol. 2010 Apr;40(4):369-72. doi: 10.1093/jjco/hyp178. Epub 2010 Mar 18. Jpn J Clin Oncol. 2010. PMID: 20299499 Clinical Trial.
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S, Sakamoto J. Tsuburaya A, et al. Among authors: sakamoto j. BMC Cancer. 2012 Jul 23;12:307. doi: 10.1186/1471-2407-12-307. BMC Cancer. 2012. PMID: 22824079 Free PMC article. Clinical Trial.
1,156 results